Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

2.

Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.

Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A.

Breast J. 2006 Jul-Aug;12(4):294-301.

PMID:
16848838
3.

Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.

Pernas S, Gil M, Benítez A, Bajen MT, Climent F, Pla MJ, Benito E, Guma A, Gutierrez C, Pisa A, Urruticoechea A, Pérez J, Gil Gil M.

Ann Surg Oncol. 2010 Mar;17(3):772-7.

PMID:
20183912
4.

Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.

Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M.

Ann Surg Oncol. 2009 Dec;16(12):3366-74. doi: 10.1245/s10434-009-0660-9. Epub 2009 Sep 4.

PMID:
19760047
5.

259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.

Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M.

Breast Cancer Res Treat. 2008 Jun;109(3):405-16. Epub 2007 Aug 9. Review.

PMID:
17687650
6.

Prognostic and therapeutic impact of sentinel node micrometastasis in patients with invasive breast cancer.

Carcoforo P, Bergossi L, Basaglia E, Soliani G, Querzoli P, Zambrini E, Pozza E, Feggi L.

Tumori. 2002 May-Jun;88(3):S4-5.

PMID:
12365385
7.

Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer.

Molland JG, Barraclough BH, Gebski V, Milliken J, Bilous M.

Aust N Z J Surg. 1996 Feb;66(2):64-70.

PMID:
8602816
8.

Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.

Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J, Lotz JP, Antoine M, Pène F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M.

Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):25-38.

PMID:
9989511
9.

The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.

Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ.

Eur J Surg Oncol. 2006 Jun;32(5):502-6. Epub 2006 Mar 29.

PMID:
16569492
10.

Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years.

Gebauer G, Fehm T, Merkle E, Jaeger W, Mitze M.

Anticancer Res. 2003 Sep-Oct;23(5b):4319-24.

PMID:
14666645
11.

Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.

Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C, Nicolò G, Schenone F, Tomei D, Cafiero F.

J Surg Oncol. 2004 Mar;85(3):102-11. Review.

PMID:
14991881
12.

Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.

Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS 3rd.

J Clin Oncol. 2008 Apr 10;26(11):1803-9. doi: 10.1200/JCO.2007.12.6425. Epub 2008 Mar 10.

PMID:
18332473
14.
15.
16.

Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.

Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA.

Cancer. 2009 Apr 15;115(8):1605-12. doi: 10.1002/cncr.24173.

17.

Clinical significance of occult micrometastases in axillary lymph nodes in "node-negative" breast cancer patients.

Umekita Y, Ohi Y, Sagara Y, Yoshida H.

Jpn J Cancer Res. 2002 Jun;93(6):695-8.

PMID:
12079518
19.

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G.

J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8.

PMID:
8931609
20.

The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up.

Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF.

Cancer. 2003 Nov 15;98(10):2105-13.

Supplemental Content

Support Center